This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's strong Q2, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
MASINegative Net Change MMSIPositive Net Change WSTNegative Net Change VEEVNegative Net Change
medical medical-devices
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
by Zacks Equity Research
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
RHHBYNegative Net Change CORTNegative Net Change ANIPPositive Net Change CMMBPositive Net Change
medical
5 Low Price-to-Book Stocks Worth Considering in October
by Kinjel Shah
STNE, CVS, KT, PAGS and ARW are five low price-to-book stocks that combine value appeal with solid growth potential.
KTPositive Net Change ARWNegative Net Change CVSNegative Net Change PAGSNegative Net Change STNENegative Net Change
business-services computers medical
Hospital Market Sneezing, But These 3 Stocks Avoiding the Cold
by Kaibalya Pravo Dey
HCA, UHS and CYH are showing strength through rising volumes and occupancy despite hospital industry headwinds.
HCANegative Net Change UHSPositive Net Change CYHNegative Net Change
hospitals medical
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
by Zacks Equity Research
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
ALNYNegative Net Change
medical
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
by Zacks Equity Research
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
ABTNegative Net Change PODDNegative Net Change PAHCNegative Net Change VCYTNegative Net Change
earnings medical medical-devices
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
by Zacks Equity Research
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
ALNYNegative Net Change BCRXNegative Net Change CRMDPositive Net Change ATXSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
by Ekta Bagri
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Teladoc Health Expands Clarity Platform With Workplace Safety Tool
by Zacks Equity Research
TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.
IRWDNegative Net Change BCRXNegative Net Change EXASNegative Net Change TDOCNegative Net Change
medical
Labcorp Gears Up to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
LH is poised for Q3 growth, with revenue and EPS estimates pointing higher as diagnostics and biopharma units deliver strong performances.
LHNegative Net Change IDXXNegative Net Change ANIPPositive Net Change EXASNegative Net Change
earnings medical medical-devices
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
by Sundeep Ganoria
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
RHHBYNegative Net Change PFENegative Net Change NVONegative Net Change
biotechs medical pharmaceuticals
Should You Buy TLRY Stock After Encouraging Q1 Results?
by Sundeep Ganoria
Tilray's return to profitability, stronger cash flow, and expanding global cannabis and beverage operations highlight its renewed growth story.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical
Can Ion Emerge as ISRG's Vehicle to Tap Ambulatory Care Growth?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform gains traction in ambulatory centers, driving 52% growth as outpatient lung diagnostics accelerate.
BSXNegative Net Change BDXNegative Net Change ISRGNegative Net Change
medical medical-devices
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
by Zacks Equity Research
WST's growth prospects remain strong, fueled by GLP-1 demand and high-value products, though tariffs and execution risks weigh on margins.
CAHNegative Net Change MASINegative Net Change MMSIPositive Net Change WSTNegative Net Change
medical medical-devices
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
by Zacks Equity Research
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
IRWDNegative Net Change AKBANegative Net Change PSTVNegative Net Change CRDLNegative Net Change PYXSPositive Net Change
medical
New Strong Sell Stocks for Oct. 15th
by Zacks Equity Research
FENC, BABA and ALCO have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2025.
ALCONegative Net Change BABANegative Net Change FENCNegative Net Change
agriculture medical retail
NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings
by Urmimala Biswas
NVDA and PLTR drive AI integration across healthcare, fueling optimism for Omnicell and Tempus AI's Q3 performance.
NVDAPositive Net Change OMCLNegative Net Change ORCLNegative Net Change PLTRPositive Net Change TEMNegative Net Change
artificial-intelligence earnings medical medical-devices robotics smart-health tech-stocks
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.
TDOCNegative Net Change AMWLNegative Net Change HIMSNegative Net Change
medical medical-devices
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation
by Zacks Equity Research
Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment.
MASINegative Net Change MMSIPositive Net Change STXSNegative Net Change WSTNegative Net Change
medical medical-devices
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
by Zacks Equity Research
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
ALNYNegative Net Change ALLOPositive Net Change CMMBPositive Net Change TVRDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
by Sundeep Ganoria
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
earnings medical pharmaceuticals
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
by Ahan Chakraborty
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
PFENegative Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?
by Zacks Equity Research
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
BCRXNegative Net Change
medical
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
by Zacks Equity Research
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
DGXNegative Net Change IDXXNegative Net Change ANIPPositive Net Change EXASNegative Net Change
earnings medical medical-devices